{"schema_version":"secwatch.filing_event.v1","accession":"0001503274-25-000002","form_type":"8-K","ticker":"QTRX","cik":"0001503274","company_name":"Quanterix Corp","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.816640+00:00","generated_at":"2026-05-28T04:52:59.994066+00:00","sec_items":["1.01","2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Quanterix to acquire Akoya Biosciences in stock deal; exchange ratio 0.318","bullets":["Akoya shareholders to receive 0.318 Quanterix shares per share; no cash consideration except for fractional shares.","Voting agreements from ~55.9% of Akoya stock and ~6.2% of Quanterix stock; lock-up agreements cover ~35.7% of QTRX shares for 90 days.","Termination fees: $7M from Akoya, $9M from Quanterix; Quanterix may provide $30M bridge convertible notes after March 15, 2025.","Expected close by July 9, 2025 (extendable to Jan 9, 2026); Akoya to nominate two directors to Quanterix board."],"urls":{"canonical":"https://secwatch.observer/filing/0001503274-25-000002","json":"https://secwatch.observer/filing/0001503274-25-000002.json","markdown":"https://secwatch.observer/filing/0001503274-25-000002.md","text":"https://secwatch.observer/filing/0001503274-25-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503274/000150327425000002/0001503274-25-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503274/000150327425000002/qtrx-20250109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:52:59.994066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}